Does rasagiline have a disease-modifying effect on Parkinson's disease?

Current Neurology and Neuroscience Reports

Volumn 10, Issue 6, 2010, Pages 413-416

  Mehta, Shyamal H ^a   Morgan, John C ^a   Sethi, Kapil D ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; RASAGILINE;

CLINICAL TRIAL; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFECT; HUMAN; NOTE; OUTCOME ASSESSMENT; PARKINSON DISEASE; TREATMENT DURATION; TREATMENT PLANNING; UNIFIED PARKINSON DISEASE RATING SCALE;

EID: 78049299951     PISSN: 15284042     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11910-010-0133-3     Document Type: Note

References (5)

1. Effect of deprenyl on the progression of disability in early Parkinson disease. The Parkinson Study Group [no authors listed]. N Engl J Med 1989, 321:1364-1371.
2. JE Ahlskog RJ Uitti 2010 Rasagiline, Parkinson neuroprotection, and delayed-start trials: still no satisfaction Neurology 74 1143 1148 1:CAS:528:DC%2BC3cXksFSitbw%3D 10.1212/WNL.0b013e3181d7d8e2 20368634
3. CE Clarke 2008 Are delayed-start design trials to show neuroprotection in Parkinson's disease fundamentally flawed? Mov Disord 23 784 7789 10.1002/mds.21918 18175348
4. A Schapira S Albrecht P Barone, et al. 2009 Immediate vs. delayed-start pramipexole in early Parkinson's disease: the PROUD study Parkinsonism Relat Disord 15 S2 S81
5. RB D'Agostino Sr 2009 The delayed start design N Engl J Med 361 1304 1306 10.1056/NEJMsm0904209 19776413